Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Mologen AG (MGNK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Mologen historical data, for real-time data please try another search
0.077 0.000    0.00%
26/11 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.068 / 0.079
  • Day's Range: 0.068 - 0.080
Type:  Equity
Market:  Germany
ISIN:  DE000A2LQ900 
WKN:  A2LQ90
Mologen 0.077 0.000 0.00%

Mologen Company Profile

 
Read the Mologen AG company profile to learn more about the business and the management team. View Mologen AG facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

43

Equity Type

ORD

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phase Ib/IIa study of lefitolimod in HIV infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany.

Contact Information

Address Fabeckstrasse 30
Berlin, 14195
Germany
Phone 49 30 84 17 880
Fax 49 30 84 17 8850
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MGNK Price Commentary

Write your thoughts about Mologen AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email